Considering the heterogeneity and the heavy crosstalk among various signaling pathways in HER2-positive breast cancer, combining information about the presence or absence of a HER2-enriched subtype with other biomarkers may help predict patient responses. This evidence concerns the gene ERBB2 and breast carcinoma.